Augmented therapeutic results elicited by splenectomy in combined modality treatment of spontaneous murine breast cancer

Summary Because it had been reported that splenectomy produces a tumor-inhibitory effect in several transplantable tumor systems when the surgery is performed before tumor challenge, we attempted to examine this putative immunological manipulation in a therapeutic situation.A spontaneous, autochthonous, murine breast tumor system was utilized in the present studies, and treatment was initiated in animals bearing large tumors (averaging 0.5 g). To amplify any immunological benefit ensuing from splenectomy, the tumor burden in the host was reduced by ancillary treatment with enucleative tumor surgery or with enucleative tumor surgery plus cytoreductive combination chemotherapy.Splenectomy performed in conjunction with enucleative tumor surgery was associated with an increment of cure in each of four separate experiments in comparison to treatment with enucleative tumor surgery alone. In four of five experiments utilizing different combinations or schedules of chemotherapeutic agents following enucleative tumor surgery, the addition of splenectomy resulted in a decrease in the rate of tumor recurrence as well as an increment in the cure rate. In the fifth experiment, splenectomy resulted in a decrease in the rate of tumor recurrence, but did not effect the ultimate cure rate.Although the nature of the immunological changes resulting from splenectomy are incompletely defined at present, these results provide encouragement in the search for immunological treatments for solid tumors.This work was supported in part by Contract No. N01-CM-73703 and Grant IR01CA-14768-01A1, both from the National Cancer Institute, National Institutes of Health, Department of Health, Education and Welfare, USA, and in part by a grant from the Chemotherapy Foundation of New York, Inc.